Prognosis and management of polymyalgia rheumatica

Article Sidebar

PDF
Published: 2011-04-23
DOI: https://doi.org/10.18051/UnivMed.2011.v30.63-70
Keywords:
Pain, stiffness, polymyalgia rheumatica, corticosteroids

Main Article Content

Diana Samara
Department of Anatomy Medical Faculty, Trisakti University

Abstract

Polymyalgia rheumatica (PMR) is commonly found in Northern Europe and in persons of Scandinavian extraction in the US, with an annual incidence of around 50 per 100,000 population over 50 years of age, in whom it should be           considered in the differential diagnosis of musculoskeletal disorders. The     disorder is twice more common in women than in men. PMR is closely related to giant cell arteritis and both disorders are considered to have a common    pathogenesis, associated with genetic and environmental factors (viral and   bacterial infections). There is no gold diagnostic standard for PMR and the diagnosis rests on a high index of suspicion in persons older than 50 years with musculoskeletal symptoms. As an aid in diagnosis, several sets of diagnostic criteria have been used, usually related to age at onset, duration, symptoms, inflammatory markers, and response to corticosteroids. Patients with PMR   usually present with acute onset of stiffness and pain in the shoulder and pelvic musculature, which may be accompanied by fever, malaise, and weight loss. The symptoms of PMR seem to be related to synovitis of proximal joints and extra-articular synovial structures. PMR may occur as an isolated syndrome or accompany other diseases, mainly giant cell arteritis. It usually responds quickly to once-daily, low-dose prednisone, but some patients require treatment for  several years. Monitoring for corticosteroid-associated side effects such as   osteoporosis and diabetes, as well as for relapses and flare-ups, is key to chronic management.

Article Details

Issue

Vol. 30 No. 1 (2011)

Section

Review Article

The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.

How to Cite

Prognosis and management of polymyalgia rheumatica. (2011). Universa Medicina, 30(1), 63-70. https://doi.org/10.18051/UnivMed.2011.v30.63-70

References

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61.

Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.

Mandell BF. Polymyalgia rheumatica: clinical presentation is key to diagnosis and treatment. Clev Clin J Med 2004;71:489-95.

Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom,1990–2001. Ann Rheum Dis 2006;65:1093–8.

Barraclough K, Liddell WG, du Toit J, Foy C, Dasgupta B, Thomas M, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Family Practice 2008;25:328–3.

Kobayashi S, Yano T, Matsumoto Y. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003;48:1532-7.

Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 2007;57:1514-9.

Chatelain D, Duhaut P, Loire R, Bosshard S, Pellet H, Piette JC, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica? Arthritis Rheum 2008;58:2565-73.

Gonzalez-Gay MA, Hajeer AH, Dababneh A. Seronegative rheumatoid arthritis in elderly and polymyalgia rheumatica have similar patterns of HLA association. J Rheumatol 2001;28:122–5.

Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark: association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996;23:112-9.

Elling H, Olsson AT, Elling P. Human Parvovirus and giant cell arteritis: a selective arteritic impact? Clin Exp Rheumatol 2000;18:Suppl 20:S12-4.

Mitchell BM, Font RL. Detection of varicella zoster virus DNA in some patient s with giant cell arteritis. Invest Ophthalmol Vis Sci 2001;42:2572-7.

Krupa WM, Dewan M, Jeon MS. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002; 161:1815-23.

Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803-9.

Frearson R, Cassidy T, Newton J. Polymyalgia rheumatica and temporal arteritis: evidence and guidelines for diagnosis and management in older people. Age Ageing 2003;32:370–4.

Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. On behalf of the BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010;49:186–90.

Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc 2006;81:1071-83.

Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372:234-45.

Stone JH, Papaliodis GN, Dunbar MR, Stone JR. A 53-year-old man with arthralgias, oral ulcers, vision loss, and vocal-cord paralysis. N Engl J Med 2010;362:537-46.

Dasgupta B, Salvaran IC, Schirmer M, Crowson CS, Maradit-Kremers H, Matteson EL and Members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Development of classification criteria for polymyalgia rheumatica (PMR): results from an expert work group meeting and a wider survey. J Rheumatol 2008;35: 270–7.

Ceccato F, Roverano SG, Papasidero S, Barrionuevo A, Rillo OL, Paira SO. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol 2006;12:167-71.

Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005;32: 65-73.

Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8.

McGonagle D, Pease C, Marzo-Ortega H, O’Connor P, Gibbon W, Emery P. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol 2001;28:1837–41.

Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C. Longitudinal examination with shoulder ultrasonography of patients with polymyalgia rheumatica. Rheumatology 2009;48:1566–9.

Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-15.

Unwin B, Williams CM, Gilliland W. Polymyalgia rheumatica and giant cell arteritis. Am Fam Physician 2006;74:1547-54.

Michet CJ, Matteson EL. Polymyalgia rheumatica. BMJ 2008;336:765-9.

Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002;287:92-101.

Knights G. Polymyalgia rheumatica and giant cell arteritis. InnovAiT 2009;2:580–4.

Hernandez-Rodriguez J, Cid MC, MD, Lopez-Soto A, Espigol-Frigole G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 2009;169:1839-50.

Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14.

American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-503.

Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 2001;30:260–7.

Pulsatelli L, Boiardi L, Pignotti. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheum 2008;59:1147–54.

Salvarani C, Cantini F, Niccoli L. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective follow up study. Arthritis Rheum 2005;53:33–8.

Martinez-Taboda VM, Bartolome MJ, Lopez-Hoyos M. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum 2004;34:454–64.

Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631-9.